###begin article-title 0
Increased Frequency and Compromised Function of T Regulatory Cells in Systemic Sclerosis (SSc) Is Related to a Diminished CD69 and TGFbeta Expression
###end article-title 0
###begin p 1
Conceived and designed the experiments: TR LvB JB MW KS WC RL. Performed the experiments: TR LvB JB MW KS YD WC. Analyzed the data: TR LvB YD. Contributed reagents/materials/analysis tools: TR AH RS RL. Wrote the paper: TR LvB JB RS RL.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 99 104 <span type="species:ncbi:9606">human</span>
Regulatory T cells (Tregs) are essential in the control of tolerance. Evidence implicates Tregs in human autoimmune conditions. Here we investigated their role in systemic sclerosis (SSc).
###end p 3
###begin title 4
Methods/Principal Findings
###end title 4
###begin p 5
###xml 488 492 488 492 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 497 498 497 498 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-</sup>
###xml 510 513 510 513 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">low</sup>
###xml 518 522 518 522 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 530 531 530 531 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 658 659 655 656 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 663 664 660 661 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 673 677 670 674 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 682 686 679 683 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 691 694 688 691 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 877 885 <span type="species:ncbi:9606">patients</span>
###xml 1008 1016 <span type="species:ncbi:9606">patients</span>
###xml 1102 1110 <span type="species:ncbi:9606">patients</span>
Patients were subdivided as having limited cutaneous SSc (lcSSc, n = 20) or diffuse cutaneous SSc (dcSSc, n = 48). Further subdivision was made between early dcSSc (n = 24) and late dcSSc (n = 24) based upon the duration of disease. 26 controls were studied for comparison. CD3+ cells were isolated using FACS and subsequently studied for the expression of CD4, CD8, CD25, FoxP3, CD127, CD62L, GITR, CD69 using flow cytometry. T cell suppression assays were performed using sorted CD4CD25highCD127- and CD4CD25lowCD127high and CD3+ cells. Suppressive function was correlated with CD69 surface expression and TGFbeta secretion/expression. The frequency of CD4+CD25+ and CD25highFoxP3highCD127neg T cells was highly increased in all SSc subgroups. Although the expression of CD25 and GITR was comparable between groups, expression of CD62L and CD69 was dramatically lower in SSc patients, which correlated with a diminished suppressive function. Co-incubation of Tregs from healthy donors with plasma from SSc patients fully abrogated suppressive activity. Activation of Tregs from healthy donors or SSc patients with PHA significantly up regulated CD69 expression that could be inhibited by SSc plasma.
###end p 5
###begin title 6
Conclusions/Significance
###end title 6
###begin p 7
These results indicate that soluble factors in SSc plasma inhibit Treg function specifically that is associated with altered Treg CD69 and TGFbeta expression. These data suggest that a defective Treg function may underlie the immune dysfunction in systemic sclerosis.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 605 608 605 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Chatenoud1">[1]</xref>
###xml 610 613 610 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-CurottodeLafaille1">[2]</xref>
###xml 615 618 615 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Sakaguchi1">[3]</xref>
###xml 620 623 620 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Singh1">[4]</xref>
###xml 625 628 625 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Takahashi1">[5]</xref>
###xml 630 633 630 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Tang1">[6]</xref>
###xml 635 638 635 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Wood1">[7]</xref>
###xml 892 895 892 895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Sakaguchi1">[3]</xref>
###xml 897 900 897 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Bach1">[8]</xref>
###xml 1131 1134 1131 1134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Salomon1">[9]</xref>
###xml 1136 1140 1136 1140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Wu1">[10]</xref>
###xml 928 932 <span type="species:ncbi:10090">mice</span>
###xml 1026 1030 <span type="species:ncbi:10090">mice</span>
Over the past decade, there have been tremendous advances in our understanding of the basic processes that control immune tolerance. It is now generally accepted that auto-reactive T cells are present in healthy individuals, but that there mere presence does not necessitate the development of autoimmune disease. The identification of CD4+CD25+ regulatory T cells (Tregs) as a crucial component of self-tolerance has opened a major area of investigation and numerous studies have demonstrated the potent influence of Tregs in suppressing autoimmune disease, transplantation and graft-versus-host disease [1], [2], [3], [4], [5], [6], [7]. Studies in rodents have provided the first evidence for the existence of a naturally occurring population of CD4+CD25+ professional regulatory/suppressor T cells, which upon in vitro TCR-mediated stimulation, suppress proliferation of effector T cells [3], [8]. In the periphery of young mice not prone to autoimmune disease, Tregs constitute a stable 10% of CD4+ T cells. In contrast, mice genetically prone to autoimmune disease such as diabetes have markedly diminished circulating Tregs [9], [10].
###end p 9
###begin p 10
###xml 314 318 314 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Shevach1">[11]</xref>
###xml 320 324 320 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-vonBoehmer1">[12]</xref>
###xml 440 444 440 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Belghith1">[13]</xref>
###xml 597 601 597 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Bluestone1">[14]</xref>
Tregs have unique and robust immunosuppressive activity. The cells require specific TCR-mediated activation to develop regulatory capacity, but their effector function appears to be nonspecific, regulating local inflammatory responses through a combination of cell-cell contact and suppressive cytokine production [11], [12]. In addition to naturally occurring Tregs, several therapeutic interventions promote Treg development and function [13]. These so-called "adaptive" Treg populations share many features attributed to natural occurring Tregs, but can differ in critical cell surface markers [14].
###end p 10
###begin p 11
###xml 405 409 401 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Ehrenstein1">[15]</xref>
###xml 585 592 581 588 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 592 596 588 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-vanAmelsfort1">[16]</xref>
###xml 753 757 749 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Jaeckel1">[17]</xref>
###xml 759 763 755 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Yan1">[18]</xref>
###xml 765 769 761 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Bonelli1">[19]</xref>
###xml 3 9 <span type="species:ncbi:9606">humans</span>
###xml 153 161 <span type="species:ncbi:9606">patients</span>
###xml 476 484 <span type="species:ncbi:9606">patients</span>
###xml 710 718 <span type="species:ncbi:9606">patients</span>
In humans, the important role of Tregs in various autoimmune diseases has been underscored by numerous seminal studies. For instance, Tregs derived from patients with rheumatoid arthritis (RA) are defective in their ability to suppress cytokine production and to convey a suppressive phenotype to CD4+ effector T cells, which was at least partly restored upon treatment of TNFalpha neutralizing therapies [15]. Moreover, the interaction of Tregs with activated monocytes from patients with RA even led to a diminished suppressive activity possibly underlying their diminished capacity in vivo[16]. Likewise, it was demonstrated by several groups that the number and suppressive capacity of Tregs is altered in patients with systemic lupus erythematosus [17], [18], [19].
###end p 11
###begin p 12
###xml 584 588 584 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Gustafsson1">[20]</xref>
###xml 590 594 590 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Hussein1">[21]</xref>
###xml 652 656 644 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Riccieri1">[22]</xref>
###xml 763 767 755 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Hussein1">[21]</xref>
###xml 769 773 761 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Kalogerou1">[23]</xref>
###xml 775 779 767 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Parel1">[24]</xref>
###xml 927 931 919 923 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-DelGaldo1">[25]</xref>
###xml 933 937 925 929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Fujii1">[26]</xref>
###xml 499 507 <span type="species:ncbi:9606">patients</span>
###xml 575 583 <span type="species:ncbi:9606">patients</span>
###xml 694 702 <span type="species:ncbi:9606">patients</span>
###xml 819 827 <span type="species:ncbi:9606">patients</span>
Systemic sclerosis (SSc) is a complex autoimmune disease characterized by an excessive deposition of matrix molecules, leading to fibrosis of multiple organs including the skin, lungs, heart and gastrointestinal tract, and often leading to severe morbidity and premature death. Although the role of immune dysfunction in the pathogenesis of SSc is currently not well understood, alterations in cellular immunity are typified by aberrant T cell biology both in the skin as well as circulation of SSc patients. For example, CD4+ T cells are increased in the circulation of SSc patients [20], [21], whereas NKT cells and gamma/delta T cells are decreased [22]. In addition, lesional skin from SSc patients displays various features consistent with T cell activation [21], [23], [24]. Finally, circulating T cells from SSc patients show altered secretion of various inflammatory mediators compared to T cells from healthy controls [25], [26].
###end p 12
###begin p 13
###xml 329 333 319 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Liu1">[27]</xref>
###xml 335 339 325 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Luo1">[28]</xref>
###xml 515 519 494 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Annunziato1">[29]</xref>
###xml 521 525 500 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Manel1">[30]</xref>
###xml 527 531 506 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Volpe1">[31]</xref>
###xml 533 537 512 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Wilson1">[32]</xref>
###xml 670 674 645 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Duan1">[33]</xref>
###xml 676 680 651 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Komura1">[34]</xref>
###xml 682 686 657 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Kurasawa1">[35]</xref>
###xml 688 692 663 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Murata1">[36]</xref>
###xml 632 640 <span type="species:ncbi:9606">patients</span>
###xml 1081 1089 <span type="species:ncbi:9606">patients</span>
###xml 1213 1221 <span type="species:ncbi:9606">patients</span>
###xml 1635 1643 <span type="species:ncbi:9606">patients</span>
T cell priming by professional antigen presenting cells is tuned by an orchestra of inflammatory mediators, of which TGFbeta, IL-23, IL-6, IL-22 and IL-1alpha are considered the most influential. For instance, in the absence of other pro-inflammatory mediators, TGFbeta production by dendritic cells induces FoxP3, a Treg marker [27], [28]. In contrast, TGFbeta in combination with IL-1alpha, IL-6 or IL-23 drives the expression of RORgammaT, a proliferation factor specific for the recently identified Th17 subset [29], [30], [31], [32]. Intriguingly, IL-23, IL-1alpha and IL-17 have been found increased in the circulation of SSc patients compared to healthy controls [33], [34], [35], [36]. Although TGFbeta is not increased in SSc plasma, multiple studies have strongly implicated this cytokine as a major stimulus of fibrosis in involved organs. Together, these observations suggest that altered Treg function might play a key role in SSc pathogenesis. To address this issue, we set out to investigate changes in the number and/or function of Tregs in the peripheral blood of patients with SSc, taking into account the different disease phenotypes. In this paper, we show that Tregs are more frequent in SSc patients but are defective in their capacity to suppress proliferation of CD4+ effector T cells. We go on to demonstrate that this diminished suppressive effect of Tregs in SSc is associated with markedly lower expression of the activation marker CD69. Finally, we show that the diminished suppressive capacity and absent upregulation of CD69 upon activation is dependent upon soluble factors present in the plasma of SSc patients. Together these data suggest that diminished T regulatory capacity is present in SSc and that the regulatory deficiency is due to circulating factors rather than an inherent defect of Tregs.
###end p 13
###begin title 14
Methods
###end title 14
###begin title 15
Ethical review board statement
###end title 15
###begin p 16
All samples were obtained with written informed consent after approval of the Institutional Review Board at the Boston University School of Medicine, Lund Univeristy medical Hospital and the Radboud University Nijmegen Medical Center.
###end p 16
###begin title 17
Study population
###end title 17
###begin p 18
###xml 311 315 311 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-1">[37]</xref>
###xml 484 488 484 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-LeRoy1">[38]</xref>
###xml 12 20 <span type="species:ncbi:9606">patients</span>
###xml 210 218 <span type="species:ncbi:9606">patients</span>
###xml 317 325 <span type="species:ncbi:9606">Patients</span>
###xml 634 642 <span type="species:ncbi:9606">patients</span>
###xml 696 704 <span type="species:ncbi:9606">patients</span>
###xml 808 816 <span type="species:ncbi:9606">Patients</span>
###xml 901 909 <span type="species:ncbi:9606">Patients</span>
Sixty-eight patients presenting to the Arthritis Center, Boston Medical Center were included in the study. This study was approved by the Boston University Medical Center Institutional Review Board. All of the patients met the American College of Rheumatology preliminary criteria for the classification of SSc [37]. Patients were subdivided as having limited cutaneous SSc (lcSSc, n = 20) or diffuse cutaneous SSc (dcSSc, n = 48) on the basis of the extent of their skin involvement [38]. A further subdivision was made between early dcSSc (n = 24) and late dcSSc (n = 24) based upon the duration of disease, defining early dcSSc as patients having a disease duration <2 years and late dcSSc as patients having a disease duration longer than 3 years. As a comparator group 26 healthy controls were studied. Patients were allowed to use low-dose prednisolone (<10 mg daily) at inclusion of the study. Patients receiving higher doses were excluded.
###end p 18
###begin title 19
Monoclonal antibodies
###end title 19
###begin p 20
###xml 177 182 <span type="species:ncbi:10090">mouse</span>
###xml 219 224 <span type="species:ncbi:9606">human</span>
###xml 526 531 <span type="species:ncbi:10090">mouse</span>
###xml 532 535 <span type="species:ncbi:10116">rat</span>
For immunostaining and analysis by fluorescence-activated cell sorting (FACS), we used phycoerythrin (PE), allophycocyanin (APC) and fluorescein isothiocynate (FITC) conjugated mouse monoclonal antibodies (mAb) against human CD4, CD8, CD25, CD69, GITR (Miltenyi Biotec Inc., CA, USA), CD127 (eBioscience, CA, USA), CD62 (BD Bioscience, NJ, USA). Intracellular staining of CD4+CD25+ cells for FoxP3 was performed using the intracellular fixation and staining procedures according to the manufacturer's protocols. Corresponding mouse/rat isotype controls were included in the analyses.
###end p 20
###begin title 21
###xml 23 24 23 24 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Isolation of PBMCs, CD3+ cells and flowcytometry
###end title 21
###begin p 22
###xml 271 272 271 272 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 1434 1438 1405 1409 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 1443 1446 1414 1417 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">low</sup>
###xml 1455 1458 1426 1429 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">low</sup>
###xml 1463 1467 1434 1438 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
PBMCs were isolated from heparinized venous blood by using density-gradient centrifugation over Ficoll-Paque (Amersham Bioscience). Next, CD3+ cells were isolated from PBMCs using CD3 microbeads according to manufacturer's protocol (Miltenyi Biotec). To this aim, 10 x 104 CD3+ cells were re-suspended in 100 microl buffer (PBS + 1% BSA) on ice. After isolation, cells were directly transferred into RPMI 1640 media supplemented with 2nM L-glutamine, 100 U/microL/ml penicillin/streptomycin (Life technologies), and 10% FBS (BioWhitacker) in 96-well U-bottom plates (Nunc). For flowcytometric analysis, CD3+ were kept on ice and washed extensively with citrated PBS containing 1% FCS. Than, after using the protocol for fixation, intra-cellular staining was achieved using 10 microl of FITC, APC or PE- conjugated antibody that was added and incubated on ice for 20 min. 300 microl FACS buffer was than added and T cells were pelleted, resuspended in 200 microl buffer, and stained for the intracellular marker FoxP3/TGFbeta were appropriate as conducted by the recommended procedure obtained from the manufacturer (Miltenyi Biotec Inc., CA, USA). Thereafter, cells were washed in buffer, fixed with 2% formaldehyde, washed again in buffer and stored at 4degreesC. The cells were analyzed using a LSRII FACScan flow cytometer (BD Biosciences) and data were processed using FlowJo software. In all experiments, the purity of CD3+, CD25highCD127low and CD25lowCD127high cells was >97%.
###end p 22
###begin title 23
###xml 15 19 15 19 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 29 32 29 32 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">low</sup>
Sorting of CD25high and CD127low cells for T cell suppression assays
###end title 23
###begin p 24
###xml 38 42 38 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 47 50 47 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">low</sup>
###xml 272 276 272 276 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 281 284 281 284 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">low</sup>
###xml 296 299 296 299 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">low</sup>
###xml 304 308 304 308 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 626 630 622 626 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 635 638 631 634 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">low</sup>
###xml 658 661 654 657 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">low</sup>
###xml 666 670 662 666 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 758 759 754 755 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 953 954 949 950 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1139 1140 1135 1136 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 907 915 <span type="species:ncbi:9606">patients</span>
For the T cell suppression assay, CD25highCD127low cells were immediately incubated with CD25-PE and CD127-FITC (eBioscience, CA, USA) antibodies for 20 minutes on ice after CD3 MACS bead isolation. Thereafter, were sorted based upon the expression of CD25 and CD127. CD25highCD127low cells, CD25lowCD127high cells and unsorted CD3+ T cells were transferred into RPMI 1640 media supplemented with 2nM L-glutamine, 100 U/microL/ml penicillin/streptomycin (Life technologies), and 10% FCS (BioWhitacker) in 96-well U-bottom plates (Nunc) until further use (overnight incubation). To assess the suppressive capacity of Treg (CD25highCD127low) and non-Treg (CD25lowCD127high) cells on unsorted CD3+ cells, unsorted T cells were brought to a concentration of 2.106 cells/ml and subsequently stimulated with phytohaemaglutinin (Sigma-Aldrich Corp, MO, USA). Both Tregs and non-Tregs from healthy controls and SSc patients were added to autologous unsorted CD3+ cells at fixed ratios 1:20 for 5 consecutive days. After 4 d of culture, [3H]Tdr was added for the remaining 24 hrs of cultures. The cells were harvested onto glass fiber filters and [3H]thymidine incorporation was assessed on a beta scintillation counter.
###end p 24
###begin title 25
Assessment of T cell suppressive effect and CD69 inducing capacity of SSc plasma
###end title 25
###begin p 26
###xml 528 532 522 526 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 537 538 531 532 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-</sup>
###xml 854 858 844 848 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 863 864 853 854 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-</sup>
###xml 137 145 <span type="species:ncbi:9606">patients</span>
###xml 223 231 <span type="species:ncbi:9606">patients</span>
###xml 404 412 <span type="species:ncbi:9606">patients</span>
###xml 585 593 <span type="species:ncbi:9606">patients</span>
The effect of SSc plasma on the suppressive capacity of healthy Treg was investigated by co-incubation with 10% or 25% plasma from edSSc patients during whole experiment. For these experiments plasma was taken from the SSc patients and healthy controls at the same time point as the T cell experiments were performed. The plasma was stored at -80degreesC until further use. Plasma from 4 different edSSc patients was used in various independent experiments. To assess the CD69 inducing capacity of SSc plasma CD3+ cells and CD25highCD127- cells were used from healthy controls and SSc patients. For this aim, both cell populations were cultured in RPMI 1640 media supplemented with 2nM L-glutamine, 100 U/microL/ml penicillin/streptomycin (Life technologies), and 10% FBS (BioWhitacker) in a 96 wells plate for 12 hours. Subsequently, CD3+ cells and CD25highCD127- cells were stimulated with either phytohaemaglutinin (PHA) only, PHA in combination with 10% plasma from an early dcSSc or plasma alone. After 12 hours of stimulation cells were analyzed on expression of CD69 by flowcytometry as previously described.
###end p 26
###begin title 27
Measurement of soluble and intracellular TGFbeta
###end title 27
###begin p 28
###xml 40 44 37 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 49 50 46 47 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-</sup>
###xml 557 561 542 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Abe1">[39]</xref>
###xml 372 376 <span type="species:ncbi:452646|species:ncbi:9666">mink</span>
Intracellular TGFbeta expression in CD25highCD127- cells was investigated using a monoclonal antibody for TGFbeta (BD Bioscience, NJ, USA) and the intracellular staining protocol as used for the FoxP3 staining. After the staining protocol, cells were fixed with 2% formaldehyde, stored at 4degreesC and analyzed on a flow cytometer the next day. TGFbeta was assayed using mink lung epithelial cells stably transfected with a plasminogen activator inhibitor-1 promoter/luciferase reporter plasmid (provided by D. Rifkin) as described previously by Abe et al [39].
###end p 28
###begin title 29
Statistical analysis
###end title 29
###begin p 30
Values are shown throughout the paper as mean+/-sem. Proportions of lymphocyte subpopulations were compared using the Student's t test for normally or not normally distributed populations where appropriate. Relationships between different values were examined using Pearson's correlation coefficient and Spearman's rank correlation tests. All statistical analyses were performed using Graphpad Prism (GraphPad Prism 4.0 by Graph Pad software Inc.)
###end p 30
###begin title 31
Results
###end title 31
###begin title 32
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 8 9 8 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 14 15 14 15 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 20 21 20 21 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-</sup>
###xml 77 85 <span type="species:ncbi:9606">patients</span>
CD4+CD25+FoxP3+CD127- cells are markedly increased in the circulation of SSc patients irrespective of disease phenotype
###end title 32
###begin p 33
###xml 268 272 268 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Liu2">[40]</xref>
###xml 274 278 274 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Ziegler1">[41]</xref>
###xml 751 758 751 758 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 1</bold>
###xml 751 758 751 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005981-t001"><bold>Table 1</bold></xref>
###xml 903 904 903 904 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 908 909 908 909 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 922 925 920 923 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs.</italic>
###xml 938 939 934 935 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 956 957 952 953 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 962 963 958 959 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 968 969 964 965 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-</sup>
###xml 981 984 975 978 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs.</italic>
###xml 997 998 989 990 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1124 1136 1116 1128 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1a, b</bold>
###xml 1124 1136 1116 1128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005981-g001"><bold>Figure 1a, b</bold></xref>
###xml 1136 1137 1128 1129 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">)</bold>
###xml 1232 1233 1224 1225 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1237 1238 1229 1230 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1240 1241 1232 1233 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1258 1259 1250 1251 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1264 1265 1256 1257 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1270 1271 1262 1263 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-</sup>
###xml 1273 1274 1265 1266 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1329 1338 1321 1330 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1b</bold>
###xml 1329 1338 1321 1330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005981-g001"><bold>Figure 1b</bold></xref>
###xml 1338 1339 1330 1331 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">)</bold>
###xml 1648 1649 1640 1641 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1654 1655 1646 1647 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1660 1661 1652 1653 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-</sup>
###xml 1883 1884 1873 1874 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1889 1890 1879 1880 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1895 1896 1885 1886 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-</sup>
###xml 2011 2017 2001 2007 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 2037 2048 2027 2038 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">very bright</sup>
###xml 2197 2209 2187 2199 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1c, d</bold>
###xml 2197 2209 2187 2199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005981-g001"><bold>Figure 1c, d</bold></xref>
###xml 2209 2210 2199 2200 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">)</bold>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 496 504 <span type="species:ncbi:9606">patients</span>
###xml 702 710 <span type="species:ncbi:9606">patients</span>
###xml 1093 1101 <span type="species:ncbi:9606">patients</span>
###xml 1290 1298 <span type="species:ncbi:9606">patients</span>
###xml 1429 1437 <span type="species:ncbi:9606">patients</span>
###xml 1581 1588 <span type="species:ncbi:9606">patient</span>
###xml 1620 1628 <span type="species:ncbi:9606">patients</span>
###xml 1719 1727 <span type="species:ncbi:9606">patients</span>
###xml 1761 1768 <span type="species:ncbi:9606">patient</span>
###xml 1912 1920 <span type="species:ncbi:9606">patients</span>
###xml 2322 2330 <span type="species:ncbi:9606">patients</span>
Human peripheral blood contains a heterogeneous subset of CD4+CD25+ T cells that comprises T regulatory cells (Tregs) and a substantial number of activated effector T cells. To date, the expression of FoxP3 and CD127 remain the best and most specific markers of Tregs [40], [41]. Since we postulated that the number and/or phenotype of Tregs in SSc is altered compared to controls, but may also differ among different clinical SSc subtypes, we here studied the number and phenotype of Tregs from patients with limited cutaneous SSc (n = 20), late diffuse cutaneous SSc (n = 24) and early diffuse SSc (n = 24) in comparison with those from healthy controls (n = 26). The clinical characteristics of all patients included in this study are presented in Table 1. Despite similar absolute numbers of CD3+ cells, flowcytometric analysis with the markers CD4, CD25, FoxP3 and CD127, demonstrated that both CD4+CD25+ (12.4+/-1.0 vs. 27.5+/-2.8, P<0.0001) and CD25+FoxP3+CD127- (2.9+/-0.5 vs. 17.3+/-1.9, P<0.0001) cells, (further designated as Tregs) are markedly increased in the circulation of SSc patients compared to controls (Figure 1a, b). Further stratification to SSc disease phenotype revealed a significantly higher number of CD4+CD25+ (P = 0.01) and CD25+FoxP3+CD127- (P = 0.01) in SSc patients with edSSc compared to ldSSc (Figure 1b), but no other significant differences between SSc phenotypes were detected. Notably, two patients with ldSSc and two with edSSc received cyclophosphamide pulse therapy for their disease. Whereas both ldSSc responded clinically well only one patient with edSSc did. In these three patients the percentage CD25+FoxP3+CD127- cells was much lower (6.0+/-2.1) compared with the other patients that were not treated. The edSSc patient that received cyclophosphamide pulse therapy but did not show a clinical response showed a frequency of 22.8% CD25+FoxP3+CD127- cells. All the patients had received cyclophosphamide longer than 3 months ago. Further analysis focusing on CD25+bright (top 10%) and CD25+very bright (top 2%) cells revealed a similar expression of the markers FoxP3 and CD127 among all individuals, both on the levels of percentage positive cells (Figure 1c, d), as well on the mean fluorescence intensity (MFI, data not shown). Taken together, these data suggest that SSc patients have a markedly increased frequency of T regulatory cells, which is not related to an altered expression of markers characterizing Treg phenotype.
###end p 33
###begin title 34
###xml 25 26 25 26 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 30 31 30 31 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 40 44 40 44 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 49 53 49 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 58 59 58 59 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-</sup>
###xml 88 96 <span type="species:ncbi:9606">patients</span>
Increased presence of CD4+CD25+ and CD25highFoxP3highCD127- cells in the circulation of patients with systemic sclerosis (SSc).
###end title 34
###begin p 35
###xml 34 35 34 35 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 39 40 39 40 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 49 53 49 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 58 62 58 62 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 67 68 67 68 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-</sup>
###xml 605 611 605 611 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 629 639 629 639 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">verybright</sup>
###xml 767 773 767 773 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 792 802 792 802 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">verybright</sup>
###xml 122 130 <span type="species:ncbi:9606">patients</span>
###xml 546 554 <span type="species:ncbi:9606">patients</span>
Flow cytometry analysis of and CD4+CD25+ and CD25highFoxP3highCD127- cells was performed in healthy controls (n = 26) and patients (n = 68) with different phenotypes of SSc. Peripheral blood mononuclear cells (PBMC's) were stained with anti-CD4, anti-CD25, anti-CD127 and anti-FoxP3, and analyzed by flow cytometry. (a) One representative individual from each group is shown. (b) Percentage of CD4+CD25+ and CD25+FoxP3+ cells are presented for each group, consisting of healthy controls (n = 26), lSSc (n = 20), ldSSc (n = 24) and edSSc (n = 24) patients. (c) Based upon CD25 expression, the top 10% (CD25bright) and top 2% (CD25verybright) were gated and FoxP3 expression analyzed as the percentage positive cells. (d) Based upon FoxP3 expression, the top 10% (FoxP3bright) and top 2% (FoxP3verybright) were gated and CD127 expression analyzed as the percentage positive cells. Data is presented as mean+/-sem.
###end p 35
###begin title 36
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients clinical characteristics.
###end title 36
###begin p 37
P value 0.03.
###end p 37
###begin title 38
###xml 70 76 70 76 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 92 102 92 102 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">verybright</sup>
###xml 112 120 <span type="species:ncbi:9606">patients</span>
Aberrant expression of phenotypic markers CD62L and CD69 on CD25+FoxP3bright and CD25+FoxP3+verybright from SSc patients
###end title 38
###begin p 39
###xml 59 60 59 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 65 66 65 66 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 71 72 71 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-</sup>
###xml 596 600 596 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Shevach2">[42]</xref>
###xml 658 664 658 664 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 680 690 680 690 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">verybright</sup>
###xml 752 753 752 753 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(</bold>
###xml 753 762 753 762 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2a</bold>
###xml 753 762 753 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005981-g002"><bold>Figure 2a</bold></xref>
###xml 762 763 762 763 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">)</bold>
###xml 828 834 828 834 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 850 860 850 860 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">verybright</sup>
###xml 1071 1072 1071 1072 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(</bold>
###xml 1072 1084 1072 1084 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2b, c</bold>
###xml 1072 1084 1072 1084 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005981-g002"><bold>Figure 2b, c</bold></xref>
###xml 1084 1085 1084 1085 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">)</bold>
###xml 1254 1258 1254 1258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Huehn1">[43]</xref>
###xml 1260 1264 1260 1264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Siegmund1">[44]</xref>
###xml 1382 1386 1379 1383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Ishikawa1">[45]</xref>
###xml 1388 1392 1385 1389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Sancho1">[46]</xref>
###xml 1406 1410 1403 1407 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 1421 1424 1416 1419 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs.</italic>
###xml 1434 1437 1427 1430 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs.</italic>
###xml 1455 1463 1446 1454 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">veryhigh</sup>
###xml 1474 1477 1463 1466 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs.</italic>
###xml 1489 1492 1476 1479 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs.</italic>
###xml 1741 1742 1726 1727 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1897 1901 1882 1886 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 1910 1914 1895 1899 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 2026 2030 2011 2015 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Afeltra1">[47]</xref>
###xml 2032 2036 2017 2021 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-FernandezGutierrez1">[48]</xref>
###xml 2038 2042 2023 2027 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-PortalesPerez1">[49]</xref>
###xml 2044 2053 2029 2038 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2d</bold>
###xml 2044 2053 2029 2038 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005981-g002"><bold>Figure 2d</bold></xref>
###xml 2053 2054 2038 2039 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">)</bold>
###xml 2307 2308 2292 2293 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(</bold>
###xml 2308 2317 2293 2302 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2e</bold>
###xml 2308 2317 2293 2302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005981-g002"><bold>Figure 2e</bold></xref>
###xml 2317 2318 2302 2303 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">)</bold>
###xml 127 135 <span type="species:ncbi:9606">patients</span>
###xml 909 917 <span type="species:ncbi:9606">patients</span>
###xml 1033 1041 <span type="species:ncbi:9606">patients</span>
###xml 1589 1597 <span type="species:ncbi:9606">patients</span>
###xml 1799 1807 <span type="species:ncbi:9606">patients</span>
###xml 2224 2232 <span type="species:ncbi:9606">patients</span>
###xml 2271 2279 <span type="species:ncbi:9606">patients</span>
Although we observed a markedly increased frequency of CD25+FoxP3+CD127- cells phenotypically representing Tregs in SSc, these patients continue to have active disease suggesting altered T cell suppressive activity. To address this, we next investigated the expression of markers potentially reflecting T cell activation including GITR, CD62L and CD69. Although the function of glucocorticoid-induced tumor necrosis factor receptor related protein (GITR) remains to be fully elucidated, it is generally accepted that GITR expression is increased upon TCR engagement, reflecting T cell activation [42]. As expected, GITR expression on CD25+Foxp3+, CD25+FoxP3+bright and CD25+FoxP3+verybright from healthy donors gradiently increased using flowcytometry (Figure 2a). In addition, the expression of GITR on CD25+FoxP3+, CD25+FoxP3+bright and CD25+FoxP3+verybright was comparable between healthy controls and SSc patients and among the investigated SSc phenotypes. In contrast, the expression of CD62L and CD69 was markedly lower in SSc patients compared to healthy controls (Figure 2b, c). CD62L is a L-selectin that is upregulated upon Treg activation and highly critical for Tregs to enter the lymph node and to carry out their local suppressive function [43], [44]. CD69 expression is pivotal for Treg function, potentially via upregulation of TGFbeta production upon cross-linking [45], [46]. CD69 on CD25high (37.0+/-5 vs. 17.6+/-5 vs. 5.3+/-2) and CD25veryhigh (35.1+/-8 vs. 17.8+/-5.7 vs. 2.4+/-0.9) T cells significantly decreased in a step-like manner, comparing healthy controls to patients with lSSc, ldSSc and edSSc phenotypes. Intriguingly, and in line with that observed in other autoimmune diseases, the expression of CD69 on CD4+ effector T cells was significantly increased in all SSc patients compared to controls and followed an inverse correlation with the CD69 expression on CD25high or FoxP3high cells suggesting, that the regulation of CD69 expression is specifically altered on the Treg population in SSc [47], [48], [49] (Figure 2d). In the search for potential SSc characteristics that might correlate with CD69 on Tregs in SSc, we found a significant association between the disease duration in lSSc patients whereas no association was present in patients either with ldSSc or edSSc (Figure 2e).
###end p 39
###begin title 40
###xml 95 103 <span type="species:ncbi:9606">patients</span>
Phenotypical characterization of T regs reveals diminished expression of CD62L and CD69 in SSc patients.
###end title 40
###begin p 41
###xml 99 105 99 105 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 114 124 114 124 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">verybright</sup>
###xml 419 425 419 425 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 507 517 507 517 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">verybright</sup>
###xml 714 720 714 720 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 729 739 729 739 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">verybright</sup>
###xml 860 866 860 866 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bright</sup>
###xml 875 885 875 885 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">verybright</sup>
###xml 182 190 <span type="species:ncbi:9606">patients</span>
###xml 332 340 <span type="species:ncbi:9606">patients</span>
###xml 527 534 <span type="species:ncbi:9606">patient</span>
###xml 693 701 <span type="species:ncbi:9606">patients</span>
###xml 755 763 <span type="species:ncbi:9606">patients</span>
###xml 903 911 <span type="species:ncbi:9606">patients</span>
###xml 957 965 <span type="species:ncbi:9606">patients</span>
###xml 1163 1171 <span type="species:ncbi:9606">patients</span>
###xml 1239 1246 <span type="species:ncbi:9606">patient</span>
###xml 1386 1394 <span type="species:ncbi:9606">patients</span>
###xml 1586 1594 <span type="species:ncbi:9606">patients</span>
Panel (a) of this figure depicts the expression of the T cell activation marker GITR on CD25+, CD25bright and CD25verybright cells from healthy controls (white bars, n = 24) and SSc patients having limited cutaneous SSc (light gray bars, n = 18), late diffuse SSc (dark gray bars, n = 22) and early diffuse SSc (black bars, n = 22) patients. In panel (b) the expression of CD62L on Tregs is investigated. CD25+ and CD25bright cells from SSc and healthy controls express similar levels of CD62L, whereas CD25verybright from SSc patient subsets exhibit lower levels of CD62L compared to those from healthy controls. Panel (c) reflects the expression of CD69 on Tregs from healthy donors and SSc patients. CD25+, CD25bright and CD25verybright cells from SSc patients express significant lower levels of CD69 than those from healthy donors. CD69 expression on CD25bright and CD25verybright cells from edSSc patients was significantly lower then that from ldSSc patients, and ldSSc expressed CD69 significantly lower than those from lSSc. In panel (d) the expression on CD3+ cells is shown for all investigated groups. In contrast with that observed on Tregs from SSc patients, CD69 expression on CD4+ cells was significantly higher in all SSc patient groups. Panel (e) reflects the potential association between CD69 expression on Tregs and disease duration. CD69 expression on T regs from patients with lSSc correlated with disease duration, whereas this was not the case either with ldSSc nor edSSc. In all figures the white bars represent healthy controls, whereas lSSc, ldSSc and edSSc patients are represented by light gray, dark gray and black bars, respectively.
###end p 41
###begin title 42
###xml 39 40 39 40 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 45 46 45 46 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 51 52 51 52 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-</sup>
###xml 81 89 <span type="species:ncbi:9606">patients</span>
Diminished suppressive capacity of CD25+FoxP3+CD127- regulatory T cells from SSc patients is correlated with CD69 expression and TGFbeta levels
###end title 42
###begin p 43
###xml 111 112 111 112 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 117 118 117 118 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 123 124 123 124 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-</sup>
###xml 312 316 312 316 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 321 324 321 324 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">low</sup>
###xml 453 454 453 454 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 628 631 626 629 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">low</sup>
###xml 636 640 634 638 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 800 809 796 805 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3a</bold>
###xml 800 809 796 805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005981-g003"><bold>Figure 3a</bold></xref>
###xml 809 810 805 806 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">)</bold>
###xml 926 927 920 921 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 952 953 944 945 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 980 981 970 971 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1073 1077 1060 1064 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Sancho1">[46]</xref>
###xml 1356 1357 1343 1344 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(</bold>
###xml 1357 1366 1344 1353 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3b</bold>
###xml 1357 1366 1344 1353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005981-g003"><bold>Figure 3b</bold></xref>
###xml 1366 1367 1353 1354 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">)</bold>
###xml 57 65 <span type="species:ncbi:9606">patients</span>
###xml 408 416 <span type="species:ncbi:9606">patients</span>
###xml 701 709 <span type="species:ncbi:9606">patients</span>
Taken together, our observations imply that although SSc patients have a significantly increased number of CD25+FoxP3+CD127- cells in the circulation, these cells phenotypically have markers suggesting impaired suppressive activity. To test the regulatory activity of these cells, we studied the capacity of CD25highCD127low cells from healthy controls (n = 8), lSSc (n = 6), ldSSc (n = 9) and edSSc (n = 8) patients to suppress the proliferation of CD4+ effector cells. As expected, Tregs from healthy controls efficiently suppressed the proliferation of CD4+ effector cells by 87.3%+/-4.9, whereas non-regulatory T cells (CD25lowCD127high) did not (8.5%+/-2.8). In contrast, Tregs obtained from SSc patients all had a markedly diminished suppressive capacity compared to those from healthy donors (Figure 3a) with T regs from lSSc, edSSc and ldSSc suppressing CD4+ effector cell proliferation by, respectively, 28.2%+/-6.0 (P = 0.0001), 56.0%+/-8.5 (P = 0.006) and 18.3%+/-5.2 (P<0.0001). Since CD69 expression by Tregs has been associated with the production of TGFbeta [46], one of key molecules implicated in suppressor activity, we investigated the possible relationship between CD69 expression and the diminished suppressive effect observed in SSc. Interestingly, the suppressive capacity correlated significantly with CD69 expression in all groups (Figure 3b).
###end p 43
###begin title 44
###xml 48 56 <span type="species:ncbi:9606">patients</span>
Impaired suppressive function by Tregs from SSc patients correlates with surface expression of CD69 and intracellular expression of TGFbeta.
###end title 44
###begin p 45
###xml 111 115 107 111 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 120 121 116 117 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-</sup>
###xml 129 132 125 128 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">low</sup>
###xml 137 141 133 137 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 204 205 200 201 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sup>
###xml 247 248 243 244 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sup>
###xml 630 634 626 630 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 639 640 635 636 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-</sup>
###xml 661 664 657 660 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">low</sup>
###xml 669 673 665 669 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 1066 1070 1062 1066 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 1075 1076 1071 1072 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-</sup>
###xml 1388 1392 1381 1385 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 1397 1398 1390 1391 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-</sup>
###xml 368 376 <span type="species:ncbi:9606">patients</span>
###xml 588 596 <span type="species:ncbi:9606">patients</span>
###xml 1327 1335 <span type="species:ncbi:9606">patients</span>
###xml 1418 1426 <span type="species:ncbi:9606">patients</span>
Unsorted CD3+ (MACS bead isolated) were stimulated with PHA (5 microg/ml) and consecutively incubated with CD25highCD127- or CD25lowCD127high cells for 5 days. Thereafter, CD3+ cells were incubated with 3H-thymidine for 24 more hours after which 3H-thymidine incorporation was measured. Panel (a) reflects the suppressive capacity of Tregs from healthy donors and SSc patients. Proliferation of CD3+ effector cells was effectively inhibited by T regulatory cells from healthy controls, whereas a clearly diminished suppressive activity was observed in the experiments with Tregs from SSc patients. Suppressive effect of Treg (CD25highCD127-) and non-Tregs (CD25lowCD127high) is presented in black and white bars, respectively. Results are the mean and SEM of 6 separate experiments using cells from healthy donors (n = 9), lSSc (n = 7), ldSSc (n = 9) and edSSc (n = 7). Panel (b) represents the correlation of CD69 expression and Treg suppressive capacity in Tregs from the various groups under investigation. The percentage of CD69 positive regulatory T cells (CD25highCD127-) correlates well with the percentage of inhibition of CD3+ cells in healthy controls (triangles), lSSc (diamonds), ldSSc (circles) and edSSc (squares). Panel (c) reflects the expression of intracellular TGFbeta in Tregs from healthy controls and SSc patients as measured using intracellular flow cytometry. CD25highCD127- cells from all SSc patients express lower TGFbeta levels compared to controls. Left panel reflects an representative individual from each group whereas the right panel displays the mean of each group comprising 6 individuals (per group) coming forth from 4 independent experiments.
###end p 45
###begin p 46
###xml 362 363 356 357 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(</bold>
###xml 363 372 357 366 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3c</bold>
###xml 363 372 357 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005981-g003"><bold>Figure 3c</bold></xref>
###xml 372 373 366 367 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">)</bold>
###xml 499 500 490 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 76 84 <span type="species:ncbi:9606">patients</span>
###xml 313 321 <span type="species:ncbi:9606">patients</span>
###xml 424 432 <span type="species:ncbi:9606">patients</span>
###xml 479 487 <span type="species:ncbi:9606">patients</span>
We next investigated the expression levels of TGFbeta in the Tregs from SSc patients compared to healthy controls and their CD45Ra+ cells. In line with the CD69, which was specifically lower on regulatory T cells in SSc, also TGFbeta expression was significantly decreased by regulatory T cells obtained from SSc patients compared to those from healthy controls (Figure 3c). TGFbeta expression on Tregs from ldSSc and edSSc patients was significantly lower compared to that from patients with lSSc (P = 0.008), whereas no difference was observed between ldSSc and edSSc. Measurement of soluble TGFbeta in the supernatant revealed no measurable TGFbeta, suggesting that TGFbeta confers its effect as membrane-bound (data not shown).
###end p 46
###begin title 47
A fraction smaller than 10kD in SSc plasma inhibits the suppressive capacity of regulatory T cells and abrogates the upregulation of CD69 specifically on regulatory T cells
###end title 47
###begin p 48
###xml 612 613 612 613 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(</bold>
###xml 613 622 613 622 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4a</bold>
###xml 613 622 613 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005981-g004"><bold>Figure 4a</bold></xref>
###xml 622 623 622 623 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">)</bold>
###xml 256 264 <span type="species:ncbi:9606">patients</span>
###xml 379 387 <span type="species:ncbi:9606">patients</span>
###xml 603 611 <span type="species:ncbi:9606">patients</span>
###xml 782 790 <span type="species:ncbi:9606">patients</span>
As inflammatory cytokines play an important role in the pathogenesis of SSc and regulatory T cell function, we next investigated whether the diminished suppressive effect of Tregs from SSc could be carried over by soluble factors in the circulation of SSc patients or alternatively could be due to an inherent defect in Tregs. Unexpectedly, the addition of 10% plasma from edSSc patients completely abrogated the suppressive capacity of Tregs on CD4+ effectors cells from healthy controls, an observation that was highly consistent throughout 5 experiments using plasma samples from 5 edSSc and 2 ldSSc patients (Figure 4a). The addition of 25% plasma had a similar effect although somewhat less potent as 10% plasma, a phenomenon that was probably caused by the TGFbeta present in patients plasma, that partly restored the suppressive capacity of Tregs. In contrast, the addition of plasma obtained from healthy controls did not have a significant effect on the suppressive capacity of Tregs.
###end p 48
###begin title 49
###xml 16 24 <span type="species:ncbi:9606">patients</span>
Plasma from SSc patients abrogates T cell suppression and up regulates CD69.
###end title 49
###begin p 50
###xml 73 77 73 77 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 82 83 82 83 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-</sup>
###xml 103 106 103 106 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">low</sup>
###xml 111 115 111 115 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 575 579 575 579 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 585 589 585 589 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 750 754 750 754 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 760 764 760 764 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 148 155 <span type="species:ncbi:9606">patient</span>
###xml 323 331 <span type="species:ncbi:9606">patients</span>
###xml 817 825 <span type="species:ncbi:9606">patients</span>
###xml 884 891 <span type="species:ncbi:9606">patient</span>
(a) During the co-cultures of unsorted CD3+ cells with either Tregs (CD25highCD127-) or non-Tregs (CD25lowCD127high) 10 or 25% plasma from an edSSc patient or healthy control was added to the culture. The graph represents data from 3 independent experiments using 3 healthy control cells, and plasma derived from two edSSc patients and two control individuals. (b) The effect of SSc plasma was evaluated by adding 10% to CD3+ cells for 24 hrs stimulated with PHA or unstimulated. As a control, CD69 expression was measured on CD3+ cells stimulated with PHA only. CD4 and CD25high/FoxP3high cells were gated based on the expression of these markers using flow cytometry. (c) CD69 expression and induction upon PHA mediated stimulation of CD4+ and CD25high/FoxP3high obtained from healthy donors, lSSc, ldSSc and edSSc patients was investigated using flow cytometry. One representative patient from each group is shown.
###end p 50
###begin p 51
###xml 277 281 277 281 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 286 289 286 289 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">low</sup>
###xml 416 420 416 420 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 425 428 425 428 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">low</sup>
###xml 437 438 437 438 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(</bold>
###xml 438 447 438 447 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4b</bold>
###xml 438 447 438 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005981-g004"><bold>Figure 4b</bold></xref>
###xml 447 448 447 448 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">)</bold>
###xml 546 547 546 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 610 611 610 611 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 710 714 710 714 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 719 722 719 722 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">low</sup>
###xml 818 822 818 822 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 827 830 827 830 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">low</sup>
###xml 1282 1283 1282 1283 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(</bold>
###xml 1283 1292 1283 1292 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4c</bold>
###xml 1283 1292 1283 1292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005981-g004"><bold>Figure 4c</bold></xref>
###xml 1292 1293 1292 1293 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">)</bold>
###xml 146 154 <span type="species:ncbi:9606">patients</span>
###xml 477 485 <span type="species:ncbi:9606">patients</span>
###xml 989 997 <span type="species:ncbi:9606">patients</span>
###xml 1149 1157 <span type="species:ncbi:9606">patients</span>
###xml 1273 1281 <span type="species:ncbi:9606">patients</span>
###xml 1444 1452 <span type="species:ncbi:9606">patients</span>
Based on our observations that CD69 expression correlates with the diminished suppressive capacity in SSc, we hypothesized that the plasma of SSc patients had a direct effect on the regulation of CD69 expression. To test this, we stimulated freshly isolated CD3+ cells and CD25highCD127low T cells from healthy controls with the potent T cell activator PHA. PHA markedly induced CD69 expression both on CD3+ and CD25highCD127low T cells (Figure 4b). However, plasma from edSSc patients also significantly increased CD69 expression on CD3+ cells (P = 0.0007) and had an additive effect in combination with PHA (P = 0.02). In contrast with the effect of plasma on CD3+ cells, the addition of edSSc plasma to CD25highCD127low T cells did not increase CD69 expression. More intriguingly, the addition of SSc plasma to CD25highCD127low T cells stimulated with PHA completely abrogated the effect of PHA. Since we observed a lower CD69 expression on regulatory T cells freshly isolated from SSc patients, we studied whether these cells still possess the ability to increase CD69 expression upon activation. Co-incubation of regulatory T cells either from patients with lSSc, ldSSc or edSSc led to an clear increase of CD69 expression that could be inhibited by plasma from edSSc patients (Figure 4c). In all experiments presented here, plasma from healthy controls was taken into account but did sort any inhibitory effects as that observed from SSc patients.
###end p 51
###begin title 52
Discussion
###end title 52
###begin p 53
###xml 102 106 102 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Parel1">[24]</xref>
###xml 108 112 108 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Boin1">[50]</xref>
###xml 114 118 114 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Scherer1">[51]</xref>
SSc is an autoimmune disease that reflects several features suggesting dysregulated T cell activation [24], [50], [51]. The data presented here suggest that dysfunctional Tregs may play an important role in SSc. We show that although the number of Tregs is markedly increased in all clinical SSc phenotypes, these Tregs have a diminished capacity to control CD4 effector T cells. Further we show that their defective function correlates with lower expression of CD69 and TGFbeta.
###end p 53
###begin p 54
###xml 279 280 279 280 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 284 285 284 285 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 395 399 395 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Bagavant1">[52]</xref>
###xml 435 436 435 436 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 440 441 440 441 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 592 596 592 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Bagavant1">[52]</xref>
###xml 598 602 598 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Scalapino1">[53]</xref>
###xml 604 608 604 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Zheng1">[54]</xref>
###xml 1062 1066 1062 1066 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Yan1">[18]</xref>
###xml 1068 1072 1068 1072 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Bonelli1">[19]</xref>
###xml 1074 1078 1074 1078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-ChowdaryVenigalla1">[55]</xref>
###xml 1080 1084 1080 1084 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Lee1">[56]</xref>
###xml 1086 1090 1086 1090 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Nadkarni1">[57]</xref>
###xml 1171 1172 1171 1172 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1176 1177 1176 1177 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1186 1187 1186 1187 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1193 1194 1193 1194 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1199 1200 1199 1200 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-</sup>
###xml 1973 1977 1973 1977 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 1982 1986 1982 1986 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 1991 1994 1991 1994 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">low</sup>
###xml 2057 2061 2057 2061 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Liu2">[40]</xref>
###xml 2063 2067 2063 2067 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Seddiki1">[58]</xref>
###xml 48 56 <span type="species:ncbi:9606">patients</span>
###xml 258 262 <span type="species:ncbi:10090">mice</span>
###xml 480 484 <span type="species:ncbi:10090">mice</span>
###xml 874 882 <span type="species:ncbi:9606">patients</span>
###xml 1047 1052 <span type="species:ncbi:9606">human</span>
###xml 2274 2282 <span type="species:ncbi:9606">patients</span>
Tregs have not been previously characterized in patients with SSc; however, they are critical in maintaining self tolerance and preventing autoimmunity. In several other autoimmune disease Tregs have been implicated in pathogenesis. For example, lupus prone mice, depleted of CD4+CD25+ cells by thymectomy, have enhanced expansion of autoreactive T cells and accelerated autoantibody production [52]. Conversely, restoration of the CD4+CD25+ cell population from syngeneic normal mice effectively abrogates the development of autoimmune disease, as has treatment with in vitro expanded Tregs [52], [53], [54]. Similar evidence originates from experimental arthritis, diabetes and multiple sclerosis models, further highlighting the crucial role of the Tregs in controlling the delicate balance between tolerance and autoimmunity. More recently, several studies performed in patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) revealed an aberrant frequency and/or function of Tregs thus indicating their crucial role in human diseases [18], [19], [55], [56], [57]. However, none of these studies reported the markedly increased frequency of CD4+CD25+ and CD25+/FoxP3+CD127- cells found in our study. In contrast, although some inconsistencies exist, most of these studies found a decreased frequency of circulating Tregs. There appear to be some discrepancies in the literature based on the sole use of CD4 and CD25 as markers for Tregs. However, co-expression of CD4 and CD25 can be induced upon multiple inflammatory events and does not necessarily guarantee suppressive capacity. Therefore, the limited use of these markers could merely reflect activation and thus lead to a false assessment of elevated Treg numbers. More recently, it has been shown that the combination of FoxP3 and CD127 expression is highly specific for discriminating Tregs from activated T cells. FoxP3 expression correlated inversely with CD127 expression, and CD4+CD25highFoxP3highCD127low cells were found to have the most potent suppressive activity [40], [58]. In the current study the combination of all these markers was used to characterize and isolate regulatory T cells, confirming our observations of a markedly increased frequency of circulating Tregs in SSc patients.
###end p 54
###begin p 55
###xml 368 372 359 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Zheng2">[59]</xref>
###xml 459 463 447 451 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 468 472 456 460 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 477 478 465 466 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-</sup>
###xml 875 876 863 864 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 880 881 868 869 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-</sup>
###xml 1053 1057 1041 1045 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Bluestone1">[14]</xref>
###xml 1164 1168 1149 1153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Asseman1">[60]</xref>
###xml 1170 1174 1155 1159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Fukaura1">[61]</xref>
###xml 585 593 <span type="species:ncbi:9606">patients</span>
###xml 624 632 <span type="species:ncbi:9606">patients</span>
###xml 805 813 <span type="species:ncbi:9606">patients</span>
TGFbeta is known to potently induce expression of the proliferation factor FoxP3, characterizing Tregs. As TGFbeta is generally accepted as the key regulator of SSc pathogenesis, the increased frequency of Tregs in SSc was not surprising. TGFbeta is crucial in the induction of FoxP3 expression and induction of suppressive activity by conversion of CD4+CD25- T cells [59]. Therefore, increased TGFbeta found in SSc might drive the increased frequency of CD25highFoxP3highCD127-. Indeed, our observation of increased FoxP3, despite comparable levels of CD25 and GITR expression in SSc patients, suggests that Tregs from SSc patients are activated to some extent. The observation that CD62L, a marker that is highly expressed on naturally occurring (thymically-derived) regulatory T cells, is lower in SSc patients suggests that these Tregs originate through conversion of CD4+CD25- T cells. These so-called "adaptive" Tregs share many features with naturally occurring Tregs, but can differ in critical cell surface biomarkers and functional attributes [14]. For instance, Tregs can mediate their suppressive effects through the production of IL-10 versus TGFbeta [60], [61].
###end p 55
###begin p 56
###xml 960 964 948 952 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Duan1">[33]</xref>
###xml 966 970 954 958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Komura1">[34]</xref>
###xml 972 976 960 964 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Kurasawa1">[35]</xref>
###xml 978 982 966 970 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Murata1">[36]</xref>
###xml 97 105 <span type="species:ncbi:9606">patients</span>
###xml 263 271 <span type="species:ncbi:9606">patients</span>
###xml 539 547 <span type="species:ncbi:9606">patients</span>
###xml 1088 1096 <span type="species:ncbi:9606">patients</span>
###xml 1144 1152 <span type="species:ncbi:9606">patients</span>
###xml 1420 1428 <span type="species:ncbi:9606">patients</span>
In contrast to CD25 and GITR expression, CD69 expression on Tregs was significantly lower in SSc patients and correlated closely with diminished suppressive activity. Further, upregulation of CD69 by T cell stimulation was completely abrogated by plasma from SSc patients, suggesting the presence of soluble factors in SSc plasma that inhibit CD69 and consequently, the suppressive capacity. Interestingly, the effect of plasma on CD69 expression was highly specific for Tregs, since CD69 regulation on other T cells was not affected. SSc patients show many features suggesting that autoimmune and inflammatory factors may stimulate profibrotic organ damage. For instance, accumulating evidence implicates inflammatory mediators in the Th17 pathway, such as IL-6, IL-1alpha, IL-23 and IL-17 itself, but also those in the Th2 (IL-10, IL-4), Th1 (IFNgamma) and other inflammatory pathways, such as IFN type I and TNFalpha, in this condition (unpublished results [33], [34], [35], [36]). It is therefore tempting to speculate that several mediators could inhibit Treg CD69 expression in SSc patients. In this light, the observation that the three patients who had a clinical response to treatment had a Treg frequency, CD69 expression and suppressive capacity that was almost comparable to that observed in healthy controls is intriguing. Whether these observations are related to lower levels of inflammatory mediators in patients with a therapeutic response will require further investigation.
###end p 56
###begin p 57
###xml 556 557 552 553 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 561 562 557 558 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 567 568 563 564 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-</sup>
###xml 608 612 604 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Ehrenstein1">[15]</xref>
###xml 614 618 610 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Nadkarni2">[62]</xref>
###xml 1091 1099 <span type="species:ncbi:9606">patients</span>
###xml 1301 1309 <span type="species:ncbi:9606">patients</span>
The potential of Tregs to modulate immune responses has led to considerable interest in their use for clinical intervention in autoimmune diseases. Two broad therapeutic applications have been considered: first, to expand the regulatory T cell compartment ex vivo with the goal of re-infusion and second, to manipulate the immune system in vivo resulting in an increase of Tregs. The latter approach has been shown to be highly applicable by seminal studies by Ehrenstein et al. in which a monoclonal antibody against TNFalpha led to a re-occurrence of CD4+CD25+CD62L- T cells with high suppressive activity [15], [62]. Of interest for the current study the suppressive effects of Tregs in these latter studies were found to be contact dependent since the neutralization of TGFbeta and IL-10 did not block the effect. This is consistent with our observation that intracellular expression of TGFbeta on Tregs corresponded well with their suppressive capacity, whereas no TGFbeta was found in the culture supernatants. In our studies we demonstrate that a soluble factors in the plasma of SSc patients is responsible for the dramatic effects observed on suppressive activity, CD69 and TGFbeta expression. In addition, we did not find evidence for an inherent defect in lower Treg CD69 expression in SSc patients, since activation of these cells led to increased expression.
###end p 57
###begin p 58
###xml 358 362 346 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Esplugues1">[63]</xref>
###xml 536 540 521 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005981-Sancho1">[46]</xref>
###xml 662 666 644 648 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 671 675 653 657 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 680 681 662 663 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-</sup>
###xml 196 200 <span type="species:ncbi:10090">mice</span>
###xml 402 406 <span type="species:ncbi:10090">mice</span>
The factors driving TGFbeta production are not well resolved. The role of CD69 in the production of TGFbeta by T cells was shown in several studies. For instance, it was demonstrated that CD69-/- mice display greatly prolonged tumor survival that was related to a decreased production of TGFbeta. CD69 engagement induced TGFbeta production by NK and T cells [63]. With respect to autoimmunity, CD69-/- mice showed a higher incidence and severity of collagen-induced arthritis, which again were correlated with reduced levels of TGFbeta [46]. The observation that CD69 surface expression closely mirrors intra-cellular TGFbeta expression both on CD45Ra as on CD25highFoxP3highCD127- cells is in line with the notion that CD69 is implicated in TGFbeta production by T regs.
###end p 58
###begin p 59
Altogether, our observations provide a rationale for therapeutic intervention to restore suppressive activity by T regs in SSc. More careful studies designed to identify the nature of factors that moderate the effects in the circulation are warranted.
###end p 59
###begin p 60
We are indebted to Mike Dimarzio who carefully performed the functional assays to measure TGFbeta.
###end p 60
###begin title 61
References
###end title 61
###begin article-title 62
Suppressor T cells-they're back and critical for regulation of autoimmunity!
###end article-title 62
###begin article-title 63
CD4(+) regulatory T cells in autoimmunity and allergy.
###end article-title 63
###begin article-title 64
Immunologic self tolerance maintained by T-cell-mediated control of self-reactive T cells: implications for autoimmunity and tumor immunity.
###end article-title 64
###begin article-title 65
Control of intestinal inflammation by regulatory T cells.
###end article-title 65
###begin article-title 66
Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4.
###end article-title 66
###begin article-title 67
Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function.
###end article-title 67
###begin article-title 68
Regulatory T cells in transplantation tolerance.
###end article-title 68
###begin article-title 69
Regulatory T cells under scrutiny.
###end article-title 69
###begin article-title 70
B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes.
###end article-title 70
###begin article-title 71
###xml 73 77 <span type="species:ncbi:10090">mice</span>
Tumor necrosis factor-alpha regulation of CD4+CD25+ T cell levels in NOD mice.
###end article-title 71
###begin article-title 72
Special regulatory T cell review: How I became a T suppressor/regulatory cell maven.
###end article-title 72
###begin article-title 73
Mechanisms of suppression by suppressor T cells.
###end article-title 73
###begin article-title 74
TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes.
###end article-title 74
###begin article-title 75
Natural versus adaptive regulatory T cells.
###end article-title 75
###begin article-title 76
Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy.
###end article-title 76
###begin article-title 77
Proinflammatory mediator-induced reversal of CD4+,CD25+ regulatory T cell-mediated suppression in rheumatoid arthritis.
###end article-title 77
###begin article-title 78
Role of regulatory T cells for the treatment of type 1 diabetes mellitus.
###end article-title 78
###begin article-title 79
Dysfunctional CD4+,CD25+ regulatory T cells in untreated active systemic lupus erythematosus secondary to interferon-alpha-producing antigen-presenting cells.
###end article-title 79
###begin article-title 80
###xml 36 44 <span type="species:ncbi:9606">patients</span>
Foxp3 expression in CD4+ T cells of patients with systemic lupus erythematosus: a comparative phenotypic analysis.
###end article-title 80
###begin article-title 81
Increase in activated T cells and reduction in suppressor inducer T cells in systemic sclerosis.
###end article-title 81
###begin article-title 82
###xml 184 192 <span type="species:ncbi:9606">patients</span>
Alterations of mononuclear inflammatory cells, CD4/CD8+ T cells, interleukin 1beta, and tumour necrosis factor alpha in the bronchoalveolar lavage fluid, peripheral blood, and skin of patients with systemic sclerosis.
###end article-title 82
###begin article-title 83
###xml 70 78 <span type="species:ncbi:9606">patients</span>
Reduced circulating natural killer T cells and gamma/delta T cells in patients with systemic sclerosis.
###end article-title 83
###begin article-title 84
###xml 41 49 <span type="species:ncbi:9606">patients</span>
Early T cell activation in the skin from patients with systemic sclerosis.
###end article-title 84
###begin article-title 85
###xml 115 123 <span type="species:ncbi:9606">patients</span>
Presence of CD4+CD8+ double-positive T cells with very high interleukin-4 production potential in lesional skin of patients with systemic sclerosis.
###end article-title 85
###begin article-title 86
T cells expressing allograft inflammatory factor 1 display increased chemotaxis and induce a profibrotic phenotype in normal fibroblasts in vitro.
###end article-title 86
###begin article-title 87
###xml 110 118 <span type="species:ncbi:9606">patients</span>
Abnormal expression of intracellular cytokines and chemokine receptors in peripheral blood T lymphocytes from patients with systemic sclerosis.
###end article-title 87
###begin article-title 88
A critical function for TGF-beta signaling in the development of natural CD4+CD25+Foxp3+ regulatory T cells.
###end article-title 88
###begin article-title 89
Dendritic cells with TGF-beta1 differentiate naive CD4+CD25- T cells into islet-protective Foxp3+ regulatory T cells.
###end article-title 89
###begin article-title 90
###xml 38 43 <span type="species:ncbi:9606">human</span>
Phenotypic and functional features of human Th17 cells.
###end article-title 90
###begin article-title 91
###xml 23 28 <span type="species:ncbi:9606">human</span>
The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat.
###end article-title 91
###begin article-title 92
###xml 128 133 <span type="species:ncbi:9606">human</span>
A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses.
###end article-title 92
###begin article-title 93
###xml 46 51 <span type="species:ncbi:9606">human</span>
Development, cytokine profile and function of human interleukin 17-producing helper T cells.
###end article-title 93
###begin article-title 94
###xml 101 109 <span type="species:ncbi:9606">patients</span>
Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma.
###end article-title 94
###begin article-title 95
###xml 34 42 <span type="species:ncbi:9606">Patients</span>
Increased Serum Interleukin 23 in Patients with Systemic Sclerosis.
###end article-title 95
###begin article-title 96
###xml 39 47 <span type="species:ncbi:9606">patients</span>
Increased interleukin-17 production in patients with systemic sclerosis.
###end article-title 96
###begin article-title 97
Clinical association of serum interleukin-17 levels in systemic sclerosis: Is systemic sclerosis a Th17 disease?
###end article-title 97
###begin article-title 98
Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.
###end article-title 98
###begin article-title 99
Criteria for the classification of early systemic sclerosis.
###end article-title 99
###begin article-title 100
An assay for transforming growth factor-beta using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct.
###end article-title 100
###begin article-title 101
###xml 77 82 <span type="species:ncbi:9606">human</span>
CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells.
###end article-title 101
###begin article-title 102
###xml 10 14 <span type="species:ncbi:10090">mice</span>
###xml 19 22 <span type="species:ncbi:9606">men</span>
FOXP3: of mice and men.
###end article-title 102
###begin article-title 103
The GITR-GITRL interaction: co-stimulation or contrasuppression of regulatory activity?
###end article-title 103
###begin article-title 104
Developmental stage, phenotype, and migration distinguish naive- and effector/memory-like CD4+ regulatory T cells.
###end article-title 104
###begin article-title 105
Migration matters: regulatory T-cell compartmentalization determines suppressive activity in vivo.
###end article-title 105
###begin article-title 106
###xml 69 75 <span type="species:ncbi:10090">murine</span>
A subset of CD4+ T cells expressing early activation antigen CD69 in murine lupus: possible abnormal regulatory role for cytokine imbalance.
###end article-title 106
###begin article-title 107
CD69 downregulates autoimmune reactivity through active transforming growth factor-beta production in collagen-induced arthritis.
###end article-title 107
###begin article-title 108
###xml 56 64 <span type="species:ncbi:9606">patients</span>
Expression of CD69 antigen on synovial fluid T cells in patients with rheumatoid arthritis and other chronic synovitis.
###end article-title 108
###begin article-title 109
Characterization and regulation of CD69 expression on rheumatoid arthritis synovial fluid T cells.
###end article-title 109
###begin article-title 110
###xml 94 102 <span type="species:ncbi:9606">patients</span>
Abnormalities in CD69 expression, cytosolic pH and Ca2+ during activation of lymphocytes from patients with systemic lupus erythematosus.
###end article-title 110
###begin article-title 111
Evaluation of topoisomerase-1-specific CD8+ T-cell response in systemic sclerosis.
###end article-title 111
###begin article-title 112
###xml 94 101 <span type="species:ncbi:9606">patient</span>
Targeting activated T cells: successful use of anti-CD25 monoclonal antibody basiliximab in a patient with systemic sclerosis.
###end article-title 112
###begin article-title 113
###xml 42 46 <span type="species:ncbi:10090">mice</span>
Failure of CD25+ T cells from lupus-prone mice to suppress lupus glomerulonephritis and sialoadenitis.
###end article-title 113
###begin article-title 114
###xml 74 78 <span type="species:ncbi:10090">mice</span>
Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells.
###end article-title 114
###begin article-title 115
CD4+ and CD8+ regulatory T cells generated ex vivo with IL-2 and TGF-beta suppress a stimulatory graft-versus-host disease with a lupus-like syndrome.
###end article-title 115
###begin article-title 116
###xml 120 128 <span type="species:ncbi:9606">patients</span>
Reduced CD4+,CD25- T cell sensitivity to the suppressive function of CD4+,CD25(high),CD127(-/low) regulatory T cells in patients with active systemic lupus erythematosus.
###end article-title 116
###begin article-title 117
Altered frequency and migration capacity of CD4+CD25+ regulatory T cells in systemic lupus erythematosus.
###end article-title 117
###begin article-title 118
###xml 74 82 <span type="species:ncbi:9606">patients</span>
Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta.
###end article-title 118
###begin article-title 119
###xml 74 79 <span type="species:ncbi:9606">human</span>
Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells.
###end article-title 119
###begin article-title 120
Generation ex vivo of TGF-beta-producing regulatory T cells from CD4+CD25- precursors.
###end article-title 120
###begin article-title 121
An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation.
###end article-title 121
###begin article-title 122
###xml 189 197 <span type="species:ncbi:9606">patients</span>
Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients.
###end article-title 122
###begin article-title 123
Dressed neurons: modeling neural-glial interactions.
###end article-title 123
###begin article-title 124
###xml 31 35 <span type="species:ncbi:10090">mice</span>
Enhanced antitumor immunity in mice deficient in CD69.
###end article-title 124
###begin p 125
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 125
###begin p 126
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: The Post-doctoral program (T.R.) was funded by the Niels-Stensen Foundation from The Netherlands. The work presented here was partly funded by the VIDI laureate (T.R) from the Dutch Organization of Research (NWO). Support was also provided by grants to R.L. from the National Institutes of Health, (NIAMS U01AR055063) and an unrestricted grant from the American Society for Scleroderma Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 126

